$2.8 Billion Biosimulation Market by Product, Application, Delivery, End User - Global Forecast to 2022: Growing Adoption of Biosimulation Software By Regulatory Bodies

Dublin, Jan. 10, 2018 -- The "Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, Regulatory) - Global Forecast to 2022" report has been added to Research and Markets' offering.

The global biosimulation market is projected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%.

Factors such as increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the market.

The report segments the global biosimulation market into by product & service, application, delivery model, end user, and region.

Based on product & service, the biosimulation market is segmented into software and services. The biosimulation software segment is expected to account for the largest market share in 2017. The high growth in this segment is attributed to the growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.

Based on application, the biosimulation market is segmented into drug discovery, drug development, and other applications (nutraceuticals, and agri-food production). The drug development segment is estimated to account for the largest market share in 2017. Biosimulation solutions help to reduce the time and cost of the drug development process by screening out flawed NCEs that have a higher probability of failure due to toxicity and poor PK/PD properties. These factors are expected to increase the adoption of biosimulation software in the drug development process and are supporting the growth of this application segment.

Based on delivery model, the biosimulation market is segmented into ownership models and subscription models. The subscription models segment is estimated to account for the largest market share in 2017. The large share of the subscription models segment is attributed to the advantages associated with these models such as cost-effectiveness, interoperability, and flexibility.

Based on end user, the biosimulation market is segmented into research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (consulting firms, defense research and development organizations, nutraceutical companies, and food and agricultural companies). In 2017, pharmaceutical and biotechnology companies are expected to form the largest share in 2017, and is projected to register the highest CAGR during the forecast period. Increased R&D budgets of pharmaceutical and biotechnology companies and increasing adoption of inorganic growth strategies by different biosimulation service providers are likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology industry.

The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes, increased use of personalized medicine, and increasing R&D expenditure by pharmaceutical and biotechnology companies.

While the emerging applications, increased use of personalized medicine, and use of biosimulation solution for pediatric drug development represents significant growth opportunities, market growth may be hindered due to lack of standardization for biosimulation solutions. The biosimulation market is highly competitive with the presence of several big and small players.

Prominent players in this market include Certara (US), Simulations Plus (US), Dassault Systmes (France), Schrdinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).

Market Dynamics

Drivers

• Increase in R&D Investments in the Pharmaceutical And Biotechnology Industries
• Growing Adoption of Biosimulation Software By Regulatory Bodies
• Technologically Advanced Qsp Systems
• Need to Curtail Drug Discovery And Development Costs
• Growth in the Biologics And Biosimilars Markets

Restraint

• Lack of Standardization

Opportunities

• Emerging Applications
• Increased Use of Personalized Medicine
• Use of Biosimulation Solution for Pediatric Drug Development

Challenges

• Difficulty in Matching the Complexity of Biological Systems And Processes
• Shortage of Biosimulation And Modeling Experts

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Biosimulation Market, By Product & Service

7 Biosimulation Market, By Application

8 Biosimulation Market, By Delivery Model

9 Biosimulation Market, By End User

10 Biosimulation Market, By Region

11 Competitive Landscape

12 Company Profiles

• Advanced Chemistry Development
• Certara
• Chemical Computing Group
• Dassault Systmes
• Evidera
• Genedata
• In Silico Biosciences
• Inosim Software
• Insilico Biotechnology
• Leadinvent Technologies
• Nuventra Pharma
• Physiomics
• Rosa
• Schrdinger
• Simulation Plus

For more information about this report visit https://www.researchandmarkets.com/research/9v77jx/2_8_billion?w=12

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Computing Services, Drug Discovery